Table 2.
The association between BDH1 mRNA expression and clinical parameters in liver cancer patients.
| BDH1 mRNA expression | ||||||
| Clinical characteristics | Variable | No. of patients | High (%) | Low (%) | χ2 | P-value |
| Age | <55 | 117 | 39 (26.53) | 78 (34.67) | 2.3656 | .1103 |
| >=55 | 255 | 108 (73.47) | 147 (65.33) | |||
| Gender | FEMALE | 121 | 37 (25.17) | 84 (37.17) | 5.3156 | .0175 |
| MALE | 252 | 110 (74.83) | 142 (62.83) | |||
| Histological type | Fibrolamellar Carcinoma | 3 | 0 (0) | 3 (1.33) | 3.9016 | .1686 |
| Hepatocellular Carcinoma | 363 | 146 (99.32) | 217 (96.02) | |||
| Hepatocholangiocarcinoma (Mixed) | 7 | 1 (0.68) | 6 (2.65) | |||
| Histologic grade | G1 | 55 | 29 (20.14) | 26 (11.61) | 19.8989 | .0001 |
| G2 | 178 | 81 (56.25) | 97 (43.3) | |||
| G3 | 123 | 33 (22.92) | 90 (40.18) | |||
| G4 | 12 | 1 (0.69) | 11 (4.91) | |||
| Stage | I | 172 | 91 (67.41) | 81 (37.85) | 32.4804 | .000 |
| II | 87 | 27 (20) | 60 (28.04) | |||
| III | 85 | 17 (12.59) | 68 (31.78) | |||
| IV | 5 | 0 (0) | 5 (2.34) | |||
| T classification | T1 | 182 | 95 (65.52) | 87 (38.5) | 31.5745 | .000 |
| T2 | 95 | 30 (20.69) | 65 (28.76) | |||
| T3 | 80 | 18 (12.41) | 62 (27.43) | |||
| T4 | 13 | 1 (0.69) | 12 (5.31) | |||
| TX | 1 | 1 (0.69) | 0 (0) | |||
| N classification | N0 | 253 | 96 (65.31) | 157 (69.78) | 3.998 | .1334 |
| N1 | 4 | 0 (0) | 4 (1.78) | |||
| NX | 115 | 51 (34.69) | 64 (28.44) | |||
| M classification | M0 | 267 | 98 (66.67) | 169 (74.78) | 6.6012 | .0352 |
| M1 | 4 | 0 (0) | 4 (1.77) | |||
| MX | 102 | 49 (33.33) | 53 (23.45) | |||
| Radiation therapy | NO | 340 | 137 (99.28) | 203 (96.67) | 1.4954 | .1531 |
| YES | 8 | 1 (0.72) | 7 (3.33) | |||
| Residual tumor | R0 | 326 | 135 (93.1) | 191 (86.43) | 5.0842 | .1395 |
| R1 | 17 | 3 (2.07) | 14 (6.33) | |||
| R2 | 1 | 0 (0) | 1 (0.45) | |||
| RX | 22 | 7 (4.83) | 15 (6.79) | |||
| Vital status | DECEASED | 130 | 36 (24.49) | 94 (41.59) | 10.7337 | .0008 |
| LIVING | 243 | 111 (75.51) | 132 (58.41) | |||
| Sample_type | Primary Tumor | 371 | 146 (99.32) | 225 (99.56) | 0 | 1 |
| Recurrent Tumor | 2 | 1 (0.68) | 1 (0.44) | |||
| Overall survival | NO | 237 | 111 (75.51) | 126 (57.27) | 12.0279 | .0004 |
| YES | 130 | 36 (24.49) | 94 (42.73) | |||
| Relapse-free survival | NO | 179 | 84 (66.14) | 95 (49.22) | 8.2226 | .0039 |
| YES | 141 | 43 (33.86) | 98 (50.78) | |||